Biogen mid-stage Alzheimer's drug trial shows cognitive decline reduction

Biogen's experimental Alzheimer's treatment demonstrated efficacy in slowing cognitive decline during Phase 2 clinical trials, with results comparable to existing FDA-approved therapies. The clinical significance remains subject to further validation in larger, late-stage trials to confirm safety and long-term durability.